Home Sleep Therapy for Older Adults With MCI

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-02-08

Study Completion Date

2026-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to learn about the ability of non-invasive brain stimulation during sleep to enhance people's deep sleep and its potential benefit on memory in people with mild cognitive impairment via home use sleep therapy device (SleepWISP) as well as learn about biomarkers associated with Alzheimer disease (AD). The clinical trial aims to answer the following main questions:

1. Whether the non-invasive transcranial electrical stimulation (TES) delivered by SleepWISP could provide short-term enhancement of deep sleep in a single night in the target population.
2. Whether TES delivered by SleepWISP could enhance deep sleep over multiple nights in the target population.
3. Whether enhance on deep sleep could improve memory performance in the target population.

Participants will be asked to wear non-invasive and painless devices that record their brain activity during sleep along with an actigraphy watch that measures their movement throughout the day. In addition, blood samples or nasal swab assays will be collected from participants multiple times during the study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Gamma-tACS on Memory and Sleep

NCT05907707

Transcranial Alternating Current Stimulation Aging Cognitive Decline +2 more

COMPLETED NA

At Home Brain Stimulation Studies of Memory and Memory Awareness

NCT04749719

Healthy

UNKNOWN NA

Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance

NCT03112902

Mild Cognitive Impairment

TERMINATED NA

Network-targeted Theta-burst Stimulation for Episodic Memory Improvement in Mild Cognitive Impairment

NCT04558164

Cognitive Dysfunction Memory Disorders in Old Age

RECRUITING NA

Improvement of Memory in Mild Cognitive Impairment

NCT05708001

Mild Cognitive Impairment

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of the present research is to evaluate the ability of non-invasive transcranial electrical stimulation (TES) during slow-wave sleep (SWS) to enhance this stage of sleep for people with mild cognitive impairment (MCI). A previous study of the investigators have demonstrated, in a pilot study, that TES can acutely (i.e., immediately after TES) increase SWS duration in healthy people. In the present proposal, the investigators aim to replicate and extend the pilot findings in seniors with MCI. It is evidenced that decline in SWS duration with aging is associated for memory impairment in seniors, which also creates risk for Alzheimer disease (AD). At the same time as conducting TES to enhance SWS sleep in seniors with MCI, the investigators also aim to explore changes in biomarkers associated with AD, including Aβ40 and Aβ42.

The investigators propose to conduct a sleep study using the Brain Electrophysiology Laboratory (BEL) company's Sleep WISP device (described in detail below). The Sleep WISP device is made up of three components: 1) 16-channel EEG amplifier with transcranial electrical stimulation (TES) capabilities, 2) a 16-channel EEG headband and 3) a small portable computer.

All participants will be provided a Sleep WISP device. Participation in the study requires that participants use the Sleep WISP when they sleep. As participants sleep, their sleep EEG will be measured and automatically scored by the computer to determine stage of sleep. When SWS is detected, low-level current (.5-1 mA total) will be applied through pre-set electrodes (four on the forehead and four at base of back of head). These electrodes were used in our pilot study, showing that current applied through these electrodes during SWS is able to increase total SWS sleep duration.

To evaluate the efficacy of the system, BEL will use a small, exploratory pilot sample of 10 employees and staff members to run the testing in Eugene, Oregon. After the 10 pilot subjects at BEL with employees and staff and prior to the main study, the protocol and system will be tested with older adults at each of the Wake Forest area (Winston-Salem, North Carolina) and Portland-Eugene surrounding area (Oregon) as pilot sub-studies for device usability feedback with seniors. These pilot subjects will only take part in the acute portion of the parent sleep study, where the first night is acclimation (no TES), the second night is TES or sham, and then a week later, they get TES or sham, for a total of three nights for the pilot studies. This pilot study does not include the PAVL memory test.

The greater study is divided into two phases.

Phase I involves up to nine sleep sessions. The first session is a baseline/acclimation session. In the first session, participants will use the Sleep WISP device to passively record sleep EEG (no TES) as baseline. The second session is performed the night following the baseline session with randomized experiment condition (either placebo or active TES session). Participants will be blinded for what condition they receive. The final session will occur one week after the second session to receive the opposite experiment condition to the second session. In the week between the second and final sessions, participants will be asked to wear the device at night to record their EEG. During this period, there will be no TES stimulation.

Phase II of the study can begin as early as the night following the completion of Phase I. To participate in Phase II participants do not need to have participated in Phase I. Phase II will follow a repeated-measures placebo-controlled design across six weeks. An equal number of participants without MCI (control group) and with MCI (experimental group) will be enrolled. Following screening and thorough training, participants will wear the WISP device for 2 weeks and receive either sham or treatment TES every night. A 2 week washout period where participants do not use the device will follow. Finally, participants will receive the remaining condition (sham or treatment) each night of the last 2 weeks of participation. Participants will also be asked to wear an actigraphy watch that measures sleep parameters based on movement each night in Phase II. A trained phlebotomist will collect blood samples or nasal swab assays from participants before and after each condition (sham and treatment; 4 total measurements) for Aβ detection.

In both Phases I and II, prior to sleep, participants will be presented with a paired-associate verbal learning (PAVL) task. Participants will be required to learn the list of words, to a pre-specified performance criterion. After waking from sleep in the morning, participants will be tested with the same list, to assess retention of the previously learned materials.

In our previous TES study of SWS enhancement, the investigators were able to show that SWS can be enhanced immediately (short-term/acute) after TES. The study was performed in the BEL sleep lab. Phase I of the proposed new study will extend the previous pilot study results by using Sleep WISP device as participants with MCI sleep at home, which will allow us to support home monitoring and acute treatment of disordered sleep for adults with MCI. Phase II will assess whether SWS modulation over multiple nights will produce cumulative enhancement of SWS in adults with MCI. In both study phases, the investigators will also evaluate the cognitive consequences, specifically declarative memory, of enhancing SWS.

Aim 1: Phase I aims to replicate our previous study (acute/short-term enhancement of SWS and safety/feasibility) in seniors with MCI with the sleep WISP device.

Aim 2: Phase II aims to assess the ability of TES to cumulatively enhance SWS over multiple sessions in seniors with MCI compared to healthy controls.

Aim 3: Evaluate SWS quality on a declarative memory task in older adults with MCI.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mild Cognitive Impairment Sleep Transcranial Electrical Stimulation Machine Learning Memory

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

During Phase I of the study, all participants receive the same amount of TES stimulations, but in randomized order (stimulation either on the second night or the last night of Phase I). All participants receive stimulation and placebo in Phase II on a daily basis for up to two weeks at a time. The order participants receive placebo or treatment in the two week blocks are randomized.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

All participants receive same amount of TES stimulations over the course of the study, but they are blind to which night or blocks of 2 weeks they receive the stimulation in Phases I and II of the study (stimulation either on the second night or the last night of Phase I and stimulation on either the first or last block of 2 weeks in Phase II).

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Deep Sleep Enhancement with TES

Transcranial Electrical Stimulation, 0.5 Hz sine wave, 0.5 mA, between frontal (frontopolar and inferior lateral frontal) and posterior (mastoid and occipital) electrodes.

Group Type EXPERIMENTAL

Transcranial Electrical Stimulation

Intervention Type DEVICE

Oscillating electrical current

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Transcranial Electrical Stimulation

Oscillating electrical current

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SleepWISP (Wireless Interface Sensor Pod)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* For participant with Amnestic MCI, the inclusion age range is 55-85 years old.
* For healthy volunteers without MCI, the inclusion age range is 40-80 years old.

Exclusion Criteria

* History of seizures
* History of epilepsy
* History of mod/severe brain injury or trauma (including neurosurgery)
* History or presence of significant neurological disease such as Parkinson
* History of Electroconvulsive Therapy (ECT)
* Presence of severe insomnia
* Presence of untreated sleep apnea
* Presence of severe anxiety or depression
* Medications that may affect the EEG
* History of stroke
* Sensitivity or allergy to lidocaine or silver
* Presence of active suicidal ideation
* Presence of metal in head or implants or medication infusion device
* Pregnancy
* Adverse reaction to TMS

Minimum Eligible Age

40 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes